Zacks Research Analysts Lower Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Zacks Research decreased their Q2 2025 EPS estimates for Axsome Therapeutics in a report issued on Tuesday, July 1st. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($1.41) per share for the quarter, down from their previous forecast of ($1.20). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' Q3 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.87) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.42 EPS, FY2026 earnings at ($0.41) EPS, Q2 2027 earnings at $0.99 EPS and FY2027 earnings at $5.18 EPS.

A number of other research firms have also recently commented on AXSM. Wells Fargo & Company restated an "overweight" rating and issued a $165.00 target price (up previously from $160.00) on shares of Axsome Therapeutics in a research note on Tuesday, May 6th. Oppenheimer assumed coverage on Axsome Therapeutics in a report on Tuesday, June 3rd. They issued an "outperform" rating and a $185.00 price objective for the company. Cantor Fitzgerald raised Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Royal Bank Of Canada reduced their target price on shares of Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a research report on Thursday, June 12th. Finally, Jefferies Financial Group began coverage on shares of Axsome Therapeutics in a research note on Monday, April 7th. They issued a "buy" rating and a $200.00 price target for the company. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $172.33.

Axsome Therapeutics Stock Up 1.4%

Axsome Therapeutics stock traded up $1.45 during trading hours on Thursday, hitting $105.36. 245,787 shares of the stock traded hands, compared to its average volume of 669,187. Axsome Therapeutics has a one year low of $72.21 and a one year high of $139.13. The firm's 50-day moving average price is $106.63 and its two-hundred day moving average price is $107.80. The company has a current ratio of 2.03, a quick ratio of 1.96 and a debt-to-equity ratio of 3.48. The company has a market cap of $5.19 billion, a PE ratio of -18.26 and a beta of 0.46.

Insider Activity

In other news, General Counsel Hunter R. Murdock sold 6,014 shares of the company's stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $100.12, for a total transaction of $602,121.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark Coleman sold 3,750 shares of the stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total value of $395,512.50. Following the sale, the director directly owned 50,387 shares in the company, valued at $5,314,316.89. This trade represents a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 93,437 shares of company stock worth $9,834,215 over the last 90 days. 22.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Axsome Therapeutics in the first quarter worth approximately $25,000. Quantbot Technologies LP purchased a new stake in Axsome Therapeutics in the first quarter worth approximately $31,000. NBC Securities Inc. purchased a new stake in Axsome Therapeutics in the first quarter worth approximately $31,000. AlphaQuest LLC bought a new stake in Axsome Therapeutics in the 1st quarter worth approximately $38,000. Finally, Neo Ivy Capital Management purchased a new position in shares of Axsome Therapeutics in the first quarter worth approximately $41,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.